Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Central Register of Clinical Trials at the Polish Ministry of Health has approved Helix BioPharma for conducting its intended Phase I/II clinical trial to evaluate the tolerability, safety and efficacy of its experimental drug L-DOS47 to treat lung cancer.
Subscribe to our email newsletter
Based on company’s DOS47 technology, L-DOS47 is intended to function by leveraging a natural process in the body called the urea cycle to produce an anti-cancer effect.
Th planned Phase I/II clinical trial is an open-label trial to investigate the ascending doses of L-DOS47 as a monotherapy, or as a combined drug with chemotherapy or radiotherapy, in patients who are suffering from inoperable, locally advanced, recurrent or metastatic, non-squamous, stage III/IV NSCLC.
Helix president John Docherty said the planned Phase I/II clinical study will employ a multi-arm design, intended to allow Helix to study the safety and preliminary efficacy of L-DOS47, both as a stand-alone therapy and in various combination chemotherapy or radiation therapy regimens.